Fees & Info

Consultation Fees

Cosmetic Injectables

Mandatory Statements:

XEOMIN® (Incobotulinumtoxin A) 50, 100 Units is a Prescription Medicine. Indications: In adults for the treatment of cervical dystonia; blepharospasm; spasticity of the upper limb; upper facial lines: glabellar frown lines, lateral periorbital lines (crows feet), horizontal forehead lines. Xeomin® has both risks and benefits, consults your doctor if Xeomin® is right for you. Further information on the risks and benefits of Xeomin® can be found in the Consumer Medicine Information (CMI) available from www.medsafe.govt.nz or by calling 0800 822 310. Use strictly as directed. If symptoms continue or you have side effects, see your doctor, pharmacist or health care professional. Common side effects include: Headaches; nausea; tenderness, swelling, redness, numbness or bruising of the skin; dry eye; heavy feeling or eyelid/eyebrow/forehead; face/brow not symmetrical. dropping eyelids/eyebrows. Serious side effects are rare and include allergic reactions. XOEMIN® is an unfunded medicine, prescription charge will apply. Normal doctor charges will still apply. Medical information: Ph 0800 822 310. Copyright 2021. Pharmacy Retailing NZ Limited t/a Health Care Logistics (HCL) 58 Richard Pearse Drive, Mangere, Auckland 2022. All rights reserved. Xeomin® and Merz Aesthetics are registered trademarks of Merz Pharma MGMbH  & Co.

Botox®, Prescription Medicine For the treatment of frown lines and crow’s feet round the eyes Botox® has risks and benefits. Ask your doctor if Botox is right for you Botulinum toxin type A 50, 100, 200 Units. For product information check with your doctor or Consumer Medicine Information on www.medsafe.govt.nz Click for further details. Allergan, Auckland.

Teosyal® from Teoxane®  are trademark of the firm TEOXANE SA. These products are gel that contains hyaluronic acid, and 0.3% by weight of lidocaine hydrochloride They are class III medical devices. Caution for people on blood thinning medicines. Local side effects: inflammatory reactions (redness, oedema, pain at the point of injection), haematomas, itching, temporary loss of sensitivity around the injected area, disorders of pigmentation in skin and hair, abscesses, indurations, nodules (possibly granulomas). General manifestations: immediate hypersensitivity up to anaphylactic shock, migration of the implant. Rare but serious adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment or blindness, skin necrosis and stroke. Lasts 9 -12 months. Please consult your doctor pharmacist for more information. Please refer to instructions for use, local distributor. Healthcare
Logistics, Auckland.

Profhilo®, containing low & high molecular weight hyaluronic acid, is a Class III medical device for the treatment of the face and body for contours redefinition and laxity remodelling where skin laxity is a problem.  Profhilo has risks and benefits. Do not use with treatments such a laser resurfacing or medium deep skin-peeling. Caution in people on blood thinning medicines. Do not inject into inflamed areas or intravenously or intramuscularly. Possible side effects: pain and swelling at injection site.  Accelagen Pty.  Ltd. Whanganui.

PROFHILO® STRUCTURA containing  low and high molecular weight Hyaluronic acid is a class 3 medical device for face  treatment and for restoring adipose tissues -in the dermal tissue repair process, and in cases of acne scars. PROFHILO® STRUCTURA has risks and benefits. Do not use it along with treatments such as laser resurfacing or medium/deep skin peeling. Do not inject into inflamed areas or intravenously or intramuscularly. Possible side effects are pain, itching or swelling at the injection site. Dermocosmetica Pty Ltd. Auckland. TAPS BG4145.

Sunekos containing hyaluronic acid and amino acids is a class III medical device that modifies the structure of mature skin, restoring volume, filling wrinkles and folds in the skin and in scar sites. Sunekos has risks and benefits. Sunekos should not be used on patients: with known hypersensitivity to any of its components; presenting with a general infection, inflammation or irritation in the area to be treated; or in patients predisposed to coagulation disorders. A local reaction may rarely occur, caused by hypersensitisation phenomena, with symptoms that include oedema and sensation of burning and/or itching. These reactions normally resolve within two days. Consult your healthcare professional to see if Sunekos is right for you. For more information refer to the instructions for use. New Zealand Sponsor: AA-Med Pty Ltd Distributed by: Xytide Biotech NZ Pty LTD